A randomized, multi-center, double-blind Phase II study of fruquintinib in patients with advanced non-small cell lung cancer (NCT02590965) (WCLC 2016)

 HMPL-013_Ph2_NSCLC_data_WCLC_2016_thumb WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer (NCT02590965)

Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wang9, Lei Yang10, Zhiwei Chen1, Xiangdong Zhou11, Zhe Liu12, Ye Hua13, Weiguo Su13

1 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China; 2 Fudan University Shanghai Cancer Center, Shanghai/China; 3 307 Hospital of the Academy of Military Medical Sciences, Beijing/China; 4 Linyi Tumor Hospital, Linyi/China; 5 West China Hospital, Chengdu/China ; 6 The First Hospital of Jilin University, Changchun/China; 7 Guangdong General Hospital, Guangzhou/China; 8 The First Affiliated Hospital, Hangzhou/China; 9 Beijing Cancer Hospital and Institute, Beijing/China; 10 Nantong Tumor Hospital, Nantong/China; 11 Xi’nan Hospital, Chongqing/China; 12 Beijing Chest Hospital, Beijing/China; 13 Hutchison MediPharma Limited, Shanghai/China

Conference: 17th World Conference on Lung Cancer
Abstract: #4571
Presenter: Shun Lu
Session: OA11 – Angiogenesis in Advanced Lung Cancer, Oral Session
Date & Time: Tuesday, December 6, 2016 (11:00 AM – 12:30 PM)

Download Presentation (PDF)